ClinicalTrials.gg
CompletedNCT01842256CKD-345Updated Aug 1, 2013

Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.

A Phase 1 interventional study of Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg and atorvastatin 40mg in Essential Hypertension and Hyperlipidemia, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-01.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical — 2 open to participants now, 2 under way, 1 of them phase 3. Essential Hypertension · Chong Kun Dang Pharmaceutical.

Enrollment
16th of 17
24 · median 169
Started
2013
with 2 others
Phase 1
6 of 18
none open now
Registered
10th of 18
by date

Among the 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2013, is one of 6 in phase 1, and was the 10th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

2 of the 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of telmisartan/s-amlodipine on the pharmacokinetic properties of atorvastatin.

Read the detailed description

healthy subjects are administrated single-dose over the period Ⅰand Ⅱ(Crossover) of telmisartan/s-amlodipine, atorvastatin and atorvastatin.

03

Conditions studied

  • Essential Hypertension
  • Hyperlipidemia

Keywords

  • Telminouveau
  • Atorvastatin
  • Pharmacokinetic
  • Healthy volunteers
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between 20 aged and 45 aged in healthy male and female
  2. Body weight more than 55kg in male, 50kg in female
  3. more than 18.5 and under 25 (Body Mass Index(kg/m2)= kg/(m)2)
  4. If female, must include more than one among the items

    1. The menopause (there is no natural menses for at least 2 years)
    2. Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or other methods of infertility condition)
    3. The male partner infertility before screening (Demonstrated azoospermia after vasectomy)and if this man is the only partner of the female subject.
    4. you are using one of the following measure for 3 months before screening, and Necessarily you agree that used continuously contraceptive measure during the clinical trial and for 1 month after the final dosing product.(But, should not use a device of contraception or oral contraceptive drug that containing a hormonal caused telmisartan, s-amlodipine, atorvastatin calcium drug interactions during the clinical trials)

      • Abstinence.
      • Physical interrupt method (such as a condom, contraceptive diaphoretic or cervical cap)
    5. In case of women of childbearing age, the serum β-hCG pregnancy test is negative, and urine β-hCG test is negative before taking the investigational product.
  5. If men has sexual life with women of childbearing age, Necessarily he agrees that use condoms during clinical trials and do not sperm donation during clinical trials and until one month after the final dosage of investigational products
  6. Those who fully understand about this clinical trial after enough hearing, and then decided to join the clinical trials by themselves and to comply with the precautions written consent.

Exclusion criteria

Exclusion Criteria:

  1. Have disease that hepatobiliary system(severe hepatic impairment, etc), kidney(severe renal impairment, etc.), nervous system, immune system, respiratory system, endocrine system,hemato-oncology disease, cardiovascular system (heart failure, etc.).or mental illness, or a history of mental disease.
  2. Have a gastrointestinal disease history that can affect drug absorption (Crohn, ulcers, etc.) or surgery (except simple appendectomy or hernia surgery)
  3. reaction to drug or clinically significant hypersensitivity reaction in the history of drugs (telmisartan, s-amlodipine or atorvastatin calcium) or additives
  4. An impossible one who participates in clinical trial including screening tests(medical history taking, BP, physical examination, 12-lead , blood \& urine laboratory test result) within 28 days before the beginning of study treatment.
  5. Defined by the following laboratory parameters:

    • , ALT> 1.25*
    • Total > 1.5* upper limit of normal range
    • CPK > 1.5* upper limit of normal range
    • (using by MDRD method) \< 60 mL/min/1.73m2
  6. Sitting SBP > 150 mmHg or \< 90 mmHg, Sitting DBP> 100 mmHg or \< 50 mmHg , after 5minuts break.
  7. Drug abuse or have a history of drug abuse showed a positive for the Triage TOX drug on urine.
  8. Pregnant or lactating women.
  9. A heavy caffeine consumer(caffeine>5cups/day), alcohol consumer(alcohol>210g/week), or smoker(cigarette>10cigarettes /day)
  10. Subject takes ethical drug or herbal medicine within 14days, OTC within 7days before the beginning of study treatment but investigator determine that the taking drug affect this study or could affect the safety of the subjects.
  11. Subject who takes inhibitors and inducers of drug metabolizing enzyme(Barbiturates etc.) within 30 days.
  12. Taking foods containing grapefruit within 7 days before the beginning of study treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days before the beginning of study treatment)
  13. Subject who treated with any investigational drugs within 60days before the beginning of study treatment (However, biologicals applies for 90 days, but can be based on a more extended period of time by considering the half-life.
  14. Previously donate whole blood within 60 days or component blood within 30days.
  15. An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
  16. Positive for , ,
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg

    Drug: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg · Drug: atorvastatin 40mg

  • Active comparator
    Atorvastatin 40mg

    Drug: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg · Drug: atorvastatin 40mg

Interventions

  • DrugTelmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg

    Drug page: Telmisartan

    * 3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one), * oral intake, once in a period * over the period Ⅰ\&Ⅱ(crossover)

  • * 1 Tablet (atorvastatin 40mg), * oral intake, once in a period * over the period Ⅰ\&Ⅱ(crossover)

06

What researchers measure

Primary outcomes

  1. In the steady state atorvastatin 40mg AUClast

    AUClast: Area under the plasma concentration time curve from zero time until the last measurable concentration.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose

  2. In the steady state atorvastatin 40mg Cmax

    Cmax: maximum plasma drug concentration

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose

Secondary outcomes

  1. In the steady state atorvastatin 40mg AUCinf

    AUCinf: Area Under the Concentration time curve from time zero to infinity

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose

  2. In the steady state atorvastatin 40mg Tmax

    Tmax: Time to Cmax

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose

  3. In the steady state atorvastatin 40mg t1/2

    t1/2: Observed terminal elimination half-life

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose

  4. Number of participants with adverse events

    * Evaluated safety parameters included: physical examination, vital sign, laboratory test, ECG * Adverse event monitoring

    Time frame: From 1day to 17days

  5. In the steady state Orthohydroxy-atorvastatin AUClast

    AUClast: Area under the plasma concentration time curve from zero time until the last measurable concentration.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose

  6. In the steady state Orthohydroxy-atorvastatin Cmax

    Cmax: maximum plasma drug concentration

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose

  7. In the steady state Orthohydroxy-atorvastatin AUCinf

    AUCinf: Area Under the Concentration time curve from time zero to infinity

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose

  8. In the steady state Orthohydroxy-atorvastatin Tmax

    Tmax: Time to Cmax

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose

  9. In the steady state Orthohydroxy-atorvastatin t1/2

    t1/2: Observed terminal elimination half-life

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose

07

Study locations

1 site
  • Severance Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of May 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2013
First posted
Apr 29, 2013
Start
Apr 2013
Primary completionActual
May 2013
CompletionActual
Jul 2013
Last update
Aug 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01842256
Responsible party
Sponsor
First posted
Apr 29, 2013
Start date
Apr 2013
Primary completion
May 2013
Completion
Jul 2013
Last update
Aug 1, 2013

Study contacts

Min Soo Park, Ph.D
principal investigator · Severance Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion